H3K4me3 Is a Potential Mediator for Antiproliferative Effects of Calcitriol (1α,25(OH)2D3) in Ovarian Cancer Biology

Han, Nan; Jeschke, Udo; Kuhn, Christina; Hester, Anna; Czogalla, Bastian; Mahner, Sven; Rottmann, Miriam; Mayr, Doris; Schmoeckel, Elisa und Trillsch, Fabian (20. März 2020): H3K4me3 Is a Potential Mediator for Antiproliferative Effects of Calcitriol (1α,25(OH)2D3) in Ovarian Cancer Biology. In: International Journal of Molecular Sciences (IJMS), Bd. 21, Nr. 6, 2151

Abstract

Abstract

Posttranslational histone modification plays an important role in tumorigenesis. Histone modification is a dynamic response of chromatin to various signals, such as the exposure to calcitriol (1α,25(OH)2D3). Recent studies suggested that histone modification levels could be used to predict patient outcomes in various cancers. Our study evaluated the expression level of histone 3 lysine 4 trimethylation (H3K4me3) in a cohort of 156 epithelial ovarian cancer (EOC) cases by immunohistochemical staining and analyzed its correlation to patient prognosis. The influence of 1α,25(OH)2D3 on the proliferation of ovarian cancer cells was measured by BrdU proliferation assay in vitro. We could show that higher levels of H3K4me3 were correlated with improved overall survival (median overall survival (OS) not reached vs. 37.0 months, p = 0.047) and identified H3K4me3 as a potential prognostic factor for the present cohort. Ovarian cancer cell 1α,25(OH)2D3 treatment induced H3K4me3 protein expression and exhibited antiproliferative effects. By this, the study suggests a possible impact of H3K4me3 expression on EOC progression as well as its relation to calcitriol (1α,25(OH)2D3) treatment. These results may serve as an explanation on how 1α,25(OH)2D3 mediates its known antiproliferative effects. In addition, they further underline the potential benefit of 1α,25(OH)2D3 supplementation in context of ovarian cancer care.

• Dokumententyp: Zeitschriftenartikel
• Publikationsform: Publisher's Version
• Keywords: 1α,25(OH)2D3; calcitriol; cell proliferation; histone 3 lysine 4 trimethylation (H3K4me3); histone modification; ovarian cancer; prognosis; vitamin D receptor
• Fakultät: Medizin > Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• Sprache: Englisch

Literaturliste

Ng J.S., Low J.J., Ilancheran A. Epithelial ovarian cancer. Best Pract. Res. Clin. Obstet. Gynaecol. 2012;26:337–345. doi: 10.1016/j.bpobgyn.2011.12.005. - DOI - PubMed Webb P.M., Jordan S.J. Epidemiology of epithelial ovarian cancer. Best Pract. Res. Clin. Obstet. Gynaecol. 2017;41:3–14. doi: 10.1016/j.bpobgyn.2016.08.006. - DOI - PubMed Schmid B.C., Oehler M.K. Improvements in progression-free and overall survival due to the use of anti-angiogenic agents in gynecologic cancers. Curr. Treat. Options Oncol. 2015;16:2. doi: 10.1007/s11864-014-0318-0. - DOI - PubMed Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 2002;3:415–428. doi: 10.1038/nrg816. - DOI - PubMed Seligson D.B., Horvath S., McBrian M.A., Mah V., Yu H., Tze S., Wang Q., Chia D., Goodglick L., Kurdistani S.K. Global levels of histone modifications predict prognosis in different cancers. Am. J. Pathol. 2009;174:1619–1628. doi: 10.2353/ajpath.2009.080874. - DOI - PMC - PubMed